| Interpretatie: | Toxische concentratie mirtazapine is onbekend.
Desmethylmirtazapine draagt niet bij aan de farmacologische werking maar wordt wel bepaald omdat de ratio meer informatie kan geven over het juiste afname moment, therapietrouw, normaal metabolisme en interacties.
Normale ratio desmethylmirtazapine - mirtazapine: 1 : 0.2 - 1.2
Bij de interpretatie van de resultaten dient rekening gehouden te worden met de meetonzekerheid van de analysemethode. Voor meer informatie kunt u terecht bij de laboratoriumapotheker. |
| Bronvermelding: | -Hiemke et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. pharmacospychiatry 44:195-235
-Grasmäder K , Verwohlt P L , Kühn K U et al. Relationship between mirtazapinedose, plasma concentration, response, and side effects in clinical practice . Pharmacopsychiatry 2005 ; 38 : 113 – 117
-Kirkton C , McIntyre I M . Therapeutic and toxic concentrations of mirtazapine . J Anal Toxicol 2006 ; 30 : 687 – 691
-Lind A B , Reis M , Bengtsson F et al. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour . Clin Pharmacokinet 2009 ; 48 : 63 – 70
-Meineke I , Kress I , Poser W et al. Therapeutic drug monitoring and its metabolite desmethylmirtazapine by HPLC with fl uorescence detection . Ther Drug Monit 2004 ; 26 : 277 – 283
-Reis M , Prochazka J , Sitsen A et al. Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study . Ther Drug Monit 2005 ; 27 : 469 – 477
-Shams M , Hiemke C , Härtter S . Therapeutic drug monitoring of antidepressant mirtazapine and its N-demethylated metabolite in human serum . Ther Drug Monit 2004 ; 26 : 78 – 84
- TDM monografie NVZA mirtazapine (www.tdm-monografie.org)
|
